Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mifepristone + oxytocin
- Development stage
- Preclinical
- Lead developer
- Population Council
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of mifepristone and oxytocin used primarily for second-trimester pregnancy termination. Mifepristone blocks progesterone receptors, sensitizing the myometrium to contractions, while oxytocin stimulates uterine contractions. This combination has shown significantly higher success rates and shorter time intervals to abortion compared to either agent alone or placebo.
02
Targets
Oxytocin receptorPR (Progesterone receptor)GR (Glucocorticoid receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on mifepristone + oxytocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mifepristone + oxytocin.